MX2018003179A - Terapia de combinación con cenicriviroc para el tratamiento de fibrosis. - Google Patents
Terapia de combinación con cenicriviroc para el tratamiento de fibrosis.Info
- Publication number
- MX2018003179A MX2018003179A MX2018003179A MX2018003179A MX2018003179A MX 2018003179 A MX2018003179 A MX 2018003179A MX 2018003179 A MX2018003179 A MX 2018003179A MX 2018003179 A MX2018003179 A MX 2018003179A MX 2018003179 A MX2018003179 A MX 2018003179A
- Authority
- MX
- Mexico
- Prior art keywords
- cenicriviroc
- ppar
- agonist
- cvc
- fibrosis
- Prior art date
Links
- PNDKCRDVVKJPKG-WHERJAGFSA-N cenicriviroc Chemical compound C1=CC(OCCOCCCC)=CC=C1C1=CC=C(N(CC(C)C)CCC\C(=C/2)C(=O)NC=3C=CC(=CC=3)[S@@](=O)CC=3N(C=NC=3)CCC)C\2=C1 PNDKCRDVVKJPKG-WHERJAGFSA-N 0.000 title abstract 5
- 229950011033 cenicriviroc Drugs 0.000 title abstract 5
- 206010016654 Fibrosis Diseases 0.000 title abstract 2
- 230000004761 fibrosis Effects 0.000 title abstract 2
- 238000002648 combination therapy Methods 0.000 title 1
- 239000000556 agonist Substances 0.000 abstract 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 abstract 2
- 102100021943 C-C motif chemokine 2 Human genes 0.000 abstract 2
- 101150023944 CXCR5 gene Proteins 0.000 abstract 2
- 102000012141 Peroxisome proliferator-activated receptor alpha Human genes 0.000 abstract 2
- 239000005557 antagonist Substances 0.000 abstract 2
- 108091008725 peroxisome proliferator-activated receptors alpha Proteins 0.000 abstract 2
- 102100031151 C-C chemokine receptor type 2 Human genes 0.000 abstract 1
- 101710149815 C-C chemokine receptor type 2 Proteins 0.000 abstract 1
- 102100035875 C-C chemokine receptor type 5 Human genes 0.000 abstract 1
- 101710149870 C-C chemokine receptor type 5 Proteins 0.000 abstract 1
- 101710155857 C-C motif chemokine 2 Proteins 0.000 abstract 1
- 102000001326 Chemokine CCL4 Human genes 0.000 abstract 1
- 108010055165 Chemokine CCL4 Proteins 0.000 abstract 1
- 102000001327 Chemokine CCL5 Human genes 0.000 abstract 1
- 108010055166 Chemokine CCL5 Proteins 0.000 abstract 1
- 102000019034 Chemokines Human genes 0.000 abstract 1
- 108010012236 Chemokines Proteins 0.000 abstract 1
- -1 MIP-1a Proteins 0.000 abstract 1
- 229930003427 Vitamin E Natural products 0.000 abstract 1
- 238000011260 co-administration Methods 0.000 abstract 1
- 229940121360 farnesoid X receptor (fxr) agonists Drugs 0.000 abstract 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 abstract 1
- 239000003446 ligand Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 229940046009 vitamin E Drugs 0.000 abstract 1
- 235000019165 vitamin E Nutrition 0.000 abstract 1
- 239000011709 vitamin E Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/5545—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having eight-membered rings not containing additional condensed or non-condensed nitrogen-containing 3-7 membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/70—Mechanisms involved in disease identification
- G01N2800/7052—Fibrosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Saccharide Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Indole Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Medicinal Preparation (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Pyrane Compounds (AREA)
Abstract
El Cenicriviroc (CVC) es un antagonista oralmente activo de unión de ligando al receptor de quimiocina C-C tipo 5 (CCR5) y el receptor de quimiocina C-C de tipo 2 (CCR2). CVC bloquea la union de RANTES, MIP-1a, y MIP-1ß a CCR5, y de MCP-1/CCL2 a CCR2. Se proporcionan en la presente métodos para tratar la fibrosis y afecciones relacionadas, que comprenden la coadministración de CVC con antagonistas de FXR, vitamina E de dosis elevada (> 400 iU/d, un agonista del receptor alfa activado por el proliferador de peroxisoma (PPAR-a), agonista PPAR-?, agonista de PPAR-d y/o agonista de quimiocina.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562219356P | 2015-09-16 | 2015-09-16 | |
| PCT/US2016/022639 WO2017048322A1 (en) | 2015-09-16 | 2016-03-16 | Cenicriviroc combination therapy for the treatment of fibrosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2018003179A true MX2018003179A (es) | 2018-08-21 |
Family
ID=58289631
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018003179A MX2018003179A (es) | 2015-09-16 | 2016-03-16 | Terapia de combinación con cenicriviroc para el tratamiento de fibrosis. |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US20180360846A1 (es) |
| EP (1) | EP3349751A4 (es) |
| JP (1) | JP2018532720A (es) |
| KR (1) | KR20180088373A (es) |
| CN (1) | CN108289881A (es) |
| AU (1) | AU2016323468A1 (es) |
| BR (1) | BR112018005163A2 (es) |
| CA (1) | CA2998509A1 (es) |
| HK (1) | HK1258396A1 (es) |
| IL (1) | IL258002A (es) |
| MX (1) | MX2018003179A (es) |
| RU (1) | RU2018113437A (es) |
| SG (1) | SG10202002323UA (es) |
| WO (1) | WO2017048322A1 (es) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008542301A (ja) | 2005-05-26 | 2008-11-27 | メタバシス・セラピューティクス・インコーポレイテッド | 脂肪性肝疾患の処置のための甲状腺ホルモン様薬剤 |
| US9719068B2 (en) | 2010-05-06 | 2017-08-01 | Children's Hospital Medical Center | Methods and systems for converting precursor cells into intestinal tissues through directed differentiation |
| CN113249297A (zh) | 2014-05-28 | 2021-08-13 | 儿童医院医疗中心 | 用于经由定向分化将前体细胞转化为胃组织的方法和系统 |
| CA2963704A1 (en) | 2014-10-17 | 2016-04-21 | Children's Hospital Medical Center | In vivo model of human small intestine using pluripotent stem cells and methods of making and using same |
| EP4177335A1 (en) | 2016-05-05 | 2023-05-10 | Children's Hospital Medical Center | Methods for the in vitro manufacture of gastric fundus tissue and compositions related to same |
| US10668108B2 (en) | 2016-11-04 | 2020-06-02 | Children's Hospital Medical Center | Compositions and methods of treating liver disease |
| BR112019010249A2 (pt) | 2016-11-21 | 2019-09-10 | Viking Therapeutics Inc | método de tratamento de doença de armazenamento de glicogênio |
| KR20230110839A (ko) | 2016-12-05 | 2023-07-25 | 칠드런즈 호스피탈 메디칼 센터 | 결장 유사장기 및 이를 제조 및 사용하는 방법 |
| MX2019007789A (es) | 2016-12-28 | 2019-10-21 | Modunex Bio Corp | Terapia de combinacion para esteatohepatitis no alcoholica (nash) y fibrosis hepatica. |
| CN110418641A (zh) | 2017-02-24 | 2019-11-05 | 基恩菲特公司 | 用于组合疗法的药物组合物 |
| AU2018280118B2 (en) | 2017-06-05 | 2021-07-15 | Viking Therapeutics, Inc. | Compositions for the treatment of fibrosis |
| CN109806386A (zh) * | 2017-11-20 | 2019-05-28 | 江苏恒瑞医药股份有限公司 | Fxr激动剂与glp-1类似物的药物组合物和用途 |
| AU2019238090B2 (en) | 2018-03-22 | 2024-08-01 | Viking Therapeutics, Inc. | Crystalline forms and methods of producing crystalline forms of a compound |
| US11813277B2 (en) | 2018-06-27 | 2023-11-14 | The Regents Of The University Of California | Methods and agents for modulating inflammation |
| US12102646B2 (en) | 2018-12-05 | 2024-10-01 | Viking Therapeutics, Inc. | Compositions for the treatment of fibrosis and inflammation |
| JP7631217B2 (ja) * | 2019-04-10 | 2025-02-18 | ジェンフィット | 式（ｉ）の化合物及びｇｌｐ－１受容体アゴニストを含む組合せ療法 |
| CN110559297B (zh) * | 2019-09-09 | 2023-03-17 | 中山大学 | 咪唑并吡啶类化合物在制备抗黄病毒属病毒感染试剂或药物中的应用 |
| KR20230013101A (ko) * | 2020-05-22 | 2023-01-26 | 메드샤인 디스커버리 아이엔씨. | 피리딘 유도체 및 이의 용도 |
| CN114028377A (zh) * | 2021-11-29 | 2022-02-11 | 中国农业大学 | 咖啡醇的医药新用途 |
| WO2023133607A1 (en) * | 2022-01-14 | 2023-07-20 | Dimerix Bioscience Pty Ltd | Compositions comprising a chemokine receptor pathway inhibitor |
| CN115006516A (zh) * | 2022-06-14 | 2022-09-06 | 四川大学华西第二医院 | Cxcl13在制备治疗nafld相关的胰岛素抵抗和肝纤维化的药物中的应用 |
| CN115414363B (zh) * | 2022-10-08 | 2023-07-07 | 湖南师范大学 | 抗肝癌组合物和苯乙双胍在制备抗肝癌药物增敏剂的应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070015796A1 (en) * | 2003-09-26 | 2007-01-18 | Smithkline Beecham Corporation | Compositions and methods for treatment of fibrosis |
| JP6087836B2 (ja) * | 2011-01-11 | 2017-03-01 | ディメリックス バイオサイエンス プロプライアタリー リミテッド | 併用療法 |
| WO2014186581A1 (en) * | 2013-05-15 | 2014-11-20 | Tobira Therapeutics, Inc. | Cenicriviroc compositions and methods of making and using the same |
| WO2015084808A1 (en) * | 2013-12-02 | 2015-06-11 | Oncomed Pharmaceuticals, Inc. | Identification of predictive biomarkers associated with wnt pathway inhibitors |
| CN105939728A (zh) * | 2014-01-31 | 2016-09-14 | 詹森药业有限公司 | 用于治疗和预防肾病和脂肪肝病的方法 |
| BR112016021682A2 (pt) * | 2014-03-21 | 2018-06-26 | Tobira Therapeutics, Inc. | cenicriviroc para o tratamento da fibrose |
| KR102387386B1 (ko) * | 2014-04-25 | 2022-04-14 | 더 존스 홉킨스 유니버시티 | 생의학적 적용에서 사용하기 위한 사이클로덱스트린 혼입된 콜라겐 매트릭스를 포함하는 조성물 |
| RU2723559C2 (ru) * | 2014-09-12 | 2020-06-16 | Тобира Терапьютикс, Инк. | Комбинированная терапия с применением препарата ценикривирок для лечения фиброза |
-
2016
- 2016-03-16 JP JP2018513847A patent/JP2018532720A/ja active Pending
- 2016-03-16 KR KR1020187010621A patent/KR20180088373A/ko not_active Ceased
- 2016-03-16 WO PCT/US2016/022639 patent/WO2017048322A1/en active Application Filing
- 2016-03-16 AU AU2016323468A patent/AU2016323468A1/en not_active Abandoned
- 2016-03-16 BR BR112018005163A patent/BR112018005163A2/pt not_active Application Discontinuation
- 2016-03-16 CN CN201680063405.7A patent/CN108289881A/zh active Pending
- 2016-03-16 US US15/759,886 patent/US20180360846A1/en not_active Abandoned
- 2016-03-16 CA CA2998509A patent/CA2998509A1/en not_active Abandoned
- 2016-03-16 RU RU2018113437A patent/RU2018113437A/ru unknown
- 2016-03-16 MX MX2018003179A patent/MX2018003179A/es unknown
- 2016-03-16 SG SG10202002323UA patent/SG10202002323UA/en unknown
- 2016-03-16 EP EP16846982.3A patent/EP3349751A4/en not_active Withdrawn
-
2018
- 2018-03-11 IL IL258002A patent/IL258002A/en unknown
-
2019
- 2019-01-17 HK HK19100803.6A patent/HK1258396A1/zh unknown
-
2020
- 2020-02-27 US US16/803,931 patent/US20200268768A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP2018532720A (ja) | 2018-11-08 |
| RU2018113437A (ru) | 2019-10-17 |
| KR20180088373A (ko) | 2018-08-03 |
| EP3349751A1 (en) | 2018-07-25 |
| CN108289881A (zh) | 2018-07-17 |
| BR112018005163A2 (pt) | 2018-10-09 |
| US20180360846A1 (en) | 2018-12-20 |
| RU2018113437A3 (es) | 2019-10-17 |
| US20200268768A1 (en) | 2020-08-27 |
| IL258002A (en) | 2018-05-31 |
| WO2017048322A1 (en) | 2017-03-23 |
| EP3349751A4 (en) | 2019-05-22 |
| SG10202002323UA (en) | 2020-05-28 |
| CA2998509A1 (en) | 2017-03-23 |
| AU2016323468A1 (en) | 2018-04-26 |
| HK1258396A1 (zh) | 2019-11-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2018003179A (es) | Terapia de combinación con cenicriviroc para el tratamiento de fibrosis. | |
| MX2017003215A (es) | Terapia de combinacion con cenicriviroc para el tratamiento de la fibrosis. | |
| PH12021550119A1 (en) | Pyridin-2-one compounds useful as smarca2 antagonists | |
| PH12017500583B1 (en) | Dihydropyrrolopyridine inhibitors of ror-gamma | |
| PH12016501457A1 (en) | Dihydropyrrolopyridine inhibitors of ror-gamma | |
| EA201990424A1 (ru) | Спиролактамовые модуляторы nmda-рецептора и их применение | |
| MX2016012365A (es) | Combinaciones. | |
| PH12022551359A1 (en) | Combination of an azetidine lpa1 receptor antagonist with pirfenidone and/or nintedanib for use in the treatment of fibrotic diseases | |
| ZA202304064B (en) | Quinoline cgas antagonist compounds | |
| MX2019001467A (es) | Combinación de antagonistas del receptor de glucagon e inhibidores de la trayectoria p13k para el tratamiento del cáncer. | |
| BR112017016428A2 (pt) | ?composto ou sal farmaceuticamente aceitável, composição farmacêutica, uso de um composto ou sal farmaceuticamente aceitável, e, método para tratamento de um distúrbio hiperproliferativo maligno, de uma condição metabólica associada à obesidade, de um distúrbio autoimune ou de um distúrbio inflamatório? | |
| MX2021004883A (es) | Metodos y composiciones para tratar apnea del sue?o. | |
| EP3632469A3 (en) | Cyp2j2 antagonists in the treatment of pain | |
| AU2014287427B2 (en) | Compositions and methods for treating neuropsychiatric disorders using an endothelin-B receptor agonist | |
| SA521421098B1 (ar) | -h4 مركبات بيريدو بيريميدينات كمثبطات مستقبل هستامين | |
| AU2016407426A1 (en) | Triple combination of pure 5-HT6 receptor antagonists, Acetylcholinesterase inhibitors and NMDA receptor antagonist | |
| AU2014365665A1 (en) | Use of PAR-1 antagonists for preventing and/or treating pelvi-perineal functional pathological conditions | |
| NZ738247A (en) | 4-(3-pyrazolylamino)-benzimidazole compounds and their use as jak1 inhibitors | |
| MA39991A (fr) | Cénicriviroc pour le traitement de l'infection à vih-2 | |
| PH12021550671A1 (en) | Prodrugs of cgrp antagonists | |
| MX2016009226A (es) | Combinaciones farmaceuticas. | |
| EA201990481A1 (ru) | Тройная комбинация обратных агонистов рецептора гистамина-3, ингибиторов ацетилхолинэстеразы и антагониста рецептора nmda | |
| NZ750150A (en) | Combination of histamine-3 receptor inverse agonists with acetylcholinesterase inhibitors | |
| PH12016502107A1 (en) | Combination of brexpiprazole and nalmefene and use thereof for treating substance-related disorders | |
| MX2014014813A (es) | Uso de agonistas o antagonistas inversos para el receptor de grelina para tratar trastornos del sueño. |